Nalbuphine+Naloxone, solution for injection

New Sale

Description

1. An entirely new combination. An original analgesic, which is not a scheduled drug.

2. The combination is in complete compliance with a global trend of multimodal analgesia. 

3.  The option for adequate pain control (equivalent to morphine) achieved with low doses and with minimal complications and adverse effects.

 

The conditions for licensing-out selling of the product.

1. Documents to be transferred:  

-     Pharmaceutical development in a CTD layout;

-    Module 3 in a CTD layout;

-    Scientific publications, literature reviews;

-    The recommended justified market price, market situation and the tentative sales targets; 

3. The generated samples for transfer and for the conduction of pre & clinical trials;

4.   The option for a technology transfer with on-site visits of specialists to the manufacturing site;

More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 949

Advertiser details

oleksandr.budiak@uf.ua
Contact Advertiser

Add comment

 
Related adverts
 

Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favourites

Sorry, you need to register or login first.

Advert search

Recent adverts

A pharmaceutical company from Turkey, selling...
330 Views
Wuxi Griffin Pharmaceuticals Co. Ltd. is...
282 Views
A pharmaceutical company from Turkey, selling...
317 Views
Active substance formulated into Tivortin®  –...
351 Views
1. An entirely new combination. An original...
310 Views
I’m a representative of Parafarm (Penza,...
1137 Views
Nonclinical study Tacrolimus caps. 0,5; 1,0; 5,0
1025 Views